DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells
Fernandes, Miguel X.
Martín, Víctor S.
Padrón, José M.
Article (Published version)
© 2017 Elsevier B.V.
MetadataShow full item record
The efficacy of microtubule targeting agents in cancer treatment has been compromised by the development of drug resistance that may involve both, P-glycoprotein overexpression and the changes in β-tubulin isoforms' expression. The anti-Topoisomerase II activity of methyl 4-((E)-2-(methoxycarbonyl)vinyloxy)oct-2-ynoate (DTA0100) was recently reported. Herein, we further evaluated this propargylic enol ether derivative and found that it exerts inhibitory effect on tubulin polymerization by binding to colchicine binding site. DTA0100 mitotic arrest properties were investigated in two multi-drug resistant cancer cell lines with P-glycoprotein overexpression (colorectal carcinoma and glioblastoma). The sensitivity of multi-drug resistant cancer cell lines to DTA0100 was not significantly changed in contrast to microtubule targeting agents such as paclitaxel, vinblastine and colchicine. DTA0100 clearly induced microtubule depolymerization, leading to disturbance of cell cycle kinetics and subsequent apoptosis. The fine-tuning in β-tubulin isoforms expression observed in multi-drug resistant cancer cells may influence the efficacy of DTA0100. Importantly, DTA0100 blocked the P-glycoprotein function in both multi-drug resistant cancer cell lines without inducing the increase in P-glycoprotein expression. Therefore, DTA0100 acting as dual inhibitor of Topoisomerase II and microtubule formation could be considered as multi-potent anticancer agent. Besides, it is able to overcome the problem of drug resistance that emerges in the therapeutic approaches with either Topoisomerase II or microtubule targeting agents.
Related to: https://ibiss-r.rcub.bg.ac.rs/handle/123456789/3873.
Keywords:β-tubulin; Colchicine; Microtubule targeting agents; Multi-drug resistance; Paclitaxel; P-glycoprotein
- Identification of predictive molecular markers for cancer progression, response to therapy and disease outcome (RS-41031)
- EU Research Potential (FP7-REGPOT- 2012-CT2012-31637-IMBRAIN)
- European Regional Development Fund (FEDER) and the Spanish MINECO (CTQ2014-56362- C2-1- P)
- COST Action CM1106 (Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells)
In: European Journal of Pharmaceutical Sciences (2017), 105: 159-168